YawYee
2021-05-31
No way
Three stocks to watch as a big annual biotech conference gets underway
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":110576387,"tweetId":"110576387","gmtCreate":1622473948949,"gmtModify":1631890829477,"author":{"id":3571654856505367,"idStr":"3571654856505367","authorId":3571654856505367,"authorIdStr":"3571654856505367","name":"YawYee","avatar":"https://static.tigerbbs.com/aa937157e1313628ba7480bd740607c1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>No way</p></body></html>","htmlText":"<html><head></head><body><p>No way</p></body></html>","text":"No way","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/110576387","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://www.laohu8.com/m/news/1104481164?lang=&edition=full","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8 <a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","MRK":"默沙东","REGN":"再生元制药公司","GILD":"吉利德科学","HOOK":"Hookipa Pharma Inc","LLY":"礼来"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/110576387"}
精彩评论